President Donald J. Trump has ordered tariffs on patented pharmaceutical products and their ingredients, invoking Section 232 of the Trade Expansion Act of 1962. The administration announced that a 100% tariff will apply to patented drug products and associated pharmaceutical ingredients, with the new duties scheduled to take effect in 120 days for certain larger companies and in 180 days for smaller firms.
The announcement also sets out distinct country-specific treatment. Pharmaceutical imports from the European Union, Japan, Korea, Switzerland and Liechtenstein will be subject to a 15% tariff. Products originating in the United Kingdom will face a lower levy under the terms of a recently concluded UK pharmaceutical agreement.
To encourage companies to shift production and pricing practices, the administration has offered carve-outs. Firms that enter into Most Favored Nation pricing agreements with the Department of Health and Human Services and simultaneously sign onshoring agreements with the Department of Commerce will receive a 0% tariff through January 20, 2029. Companies that opt only to enter onshoring agreements with the Department of Commerce will face a 20% tariff.
The measure does not extend to all pharmaceutical categories. Generic drugs, biosimilars and their associated ingredients are exempt from tariffs at present; the administration said this exemption will be reassessed in one year. In addition, orphan drugs, animal health medicines and certain other specialty pharmaceutical products will be excluded from tariffs if they come from trade deal countries or if they are deemed to meet an urgent public health need.
The tariffs follow a Section 232 investigation conducted by the Secretary of Commerce, which concluded that imports of patented pharmaceuticals and related ingredients are occurring in volumes that threaten to impair national security. As part of the policy response, the administration said the impending tariffs have prompted approximately $400 billion in new investment commitments from U.S. and foreign pharmaceutical companies. Those commitments are slated to be spent in the United States during President Trump’s current term in office.
The timetable for implementation, the country-specific rates, the carve-outs tied to pricing and onshoring agreements, and the one-year reassessment for generics are all specified elements of the policy as announced. The administration also set a sunset condition for the 0% tariff tied to compliance through January 20, 2029.
Implementation details
- 100% tariff on patented pharmaceutical products and associated ingredients - effective in 120 days for certain large companies, 180 days for smaller companies.
- 15% tariff for products from the EU, Japan, Korea, Switzerland and Liechtenstein.
- Lower tariff for UK pharmaceutical products under a UK pharmaceutical agreement.
- 0% tariff through January 20, 2029 for companies that sign Most Favored Nation pricing agreements with HHS and onshoring agreements with Commerce; 20% tariff for companies that sign only onshoring agreements with Commerce.
- Generics, biosimilars and related ingredients exempt for now; reassessment in one year. Orphan drugs, animal health drugs and certain specialty products may be exempt if from trade deal countries or meeting urgent public health needs.
This report focuses on the announced tariffs, the conditions for exemptions and incentives, and the investment commitments cited by the administration. It reflects the measures and timelines as released in the announcement.